Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 15,230 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 15,230 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 17,126 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 17,126 · Balance 17,126 F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2024 Filed Mar 22, 2024 23:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 13,278 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001415889-24-009019 · form4-03222024_110316.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,571 Underlying: Common Stock · 13,278 shares Expires 2032-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F4 · derivative.exercise_date: The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter. F2 · balance_after: The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 23:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 13,278 | $19.16 | $254,462.25 |
DisclosureSEC source: 0001415889-24-009019 · form4-03222024_110316.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 23:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 13,278 | $5.52 | $73,294.56 |
DisclosureSEC source: 0001415889-24-009019 · form4-03222024_110316.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F2 · balance_after: The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:41 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 16,835 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004006 · form4-02162024_010242.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,835 Underlying: Common Stock · 16,835 shares Expires 2034-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 21, 2024 00:24 UTC Amendment | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 23,364 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004482 · form4a-02212024_120256.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,364 Underlying: Common Stock · 23,364 shares Expires 2034-02-13 F1 · shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F1 · balance_after: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000129 · wk-form4_1692129995.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,604 Underlying: Common stock · 2,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000129 · wk-form4_1692129995.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 18,958 | $0.00 Strike: $26.56 | $0.00 |
DisclosureSEC source: 0001439222-23-000079 · wk-form4_1686860710.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,958 Underlying: Common stock · 18,958 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000079 · wk-form4_1686860710.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,388 Underlying: Common stock · 3,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 23, 2023 Filed Apr 7, 2023 00:15 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 27,567 | $0.00 Strike: $25.28 | $0.00 |
DisclosureSEC source: 0001209191-23-023661 · doc4.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,567 Underlying: Common Stock · 27,567 shares Expires 2033-02-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 01:25 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 32,861 | $4.66 | $153,132.26 |
DisclosureSEC source: 0001209191-23-012015 · doc4.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,835 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 23:24 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 11,313 | $3.91 | $44,233.83 |
DisclosureSEC source: 0001209191-23-005993 · doc4.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,696 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:31 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 6,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000084 · wf-form4_166060255599985.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,906 Underlying: Common stock · 6,906 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:31 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 37,947 | $0.00 Strike: $25.99 | $0.00 |
DisclosureSEC source: 0001439222-22-000084 · wf-form4_166060255599985.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,947 Underlying: Common stock · 37,947 shares Expires 2032-08-11 F1 · derivative.exercise_date: This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:02 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 131,400 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005942 · doc4.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,400 Underlying: Common Stock · 131,400 shares Expires 2032-01-27 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:02 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantCommon Stock | 131,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005942 · doc4.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,009 F1 · shares: The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:44 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 133,350 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001209191-21-006453 · doc4.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,350 Underlying: Common Stock · 133,350 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:47 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,999 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-20-064659 · doc4.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,999 Underlying: Common Stock · 4,999 shares Expires 2028-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on May 29, 2019 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:47 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 4,999 | $25.00 | $124,975.00 |
DisclosureSEC source: 0001209191-20-064659 · doc4.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Ballal's trading plan under Rule 10b5-1. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:47 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionCommon Stock | 4,999 | $3.15 | $15,746.85 |
DisclosureSEC source: 0001209191-20-064659 · doc4.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-20-063780 · doc4.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,998 Underlying: Common Stock · 1 shares Expires 2028-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on May 29, 2019 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 1 | $25.00 | $25.00 |
DisclosureSEC source: 0001209191-20-063780 · doc4.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Ballal's trading plan under Rule 10b5-1. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionCommon Stock | 1 | $3.15 | $3.15 |
DisclosureSEC source: 0001209191-20-063780 · doc4.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.